Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Pilot Study of Subsequent Line Gemcitabine and Nivolumab for Advanced SCLC

NCT03662074 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.

NCT NCT03662074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03662074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Pilot Study of Subsequent Line Gemcitabine and Nivolumab for Advanced SCLC
Lead sponsor
Wake Forest University Health Sciences
Phase
Phase 2
Overall status
Terminated
Start date
November 7, 2018
Completion date
February 3, 2022
Enrollment
14 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung carcinoma, stage iv lung cancer ajcc v8, stage iva lung cancer ajcc v8, stage ivb lung cancer ajcc v8